Top Markets
Coin of the day
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
Rang in Aktien #39496
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
Aktienkurs
$0.1174299
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$467.84K
Veränderung (1 Tag)
-8.57%
Veränderung (1 Jahr)
1.38%
Land
CA
Handel Vaxil Bio Ltd. (VXL)

Kategorie

Kursverlauf für Vaxil Bio Ltd. (VXL)
Höchster Schlusskurs: $0.13 am 2026-08-01

Niedrigster Schlusskurs: $137.64 am 2010-03-01
Kursverlauf der Aktie von Vaxil Bio Ltd. von 2010 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 24.66%
2025 -72.61%
2024 -24.06%
2023 -28.26%
2022 -76.68%
2021 -41.79%
2020 258.87%
2019 16.10%
2018 -52.29%
2017 -41.76%
2016 16.83%
2015 -19.78%
2014 -67.07%
2013 -46.95%
2012 -44.33%
2011 -48.81%
2010 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$517.18 32.51%
US
$857.76 31.47%
NL
$731.17 7.05%
CH
$1.07K -6.40%
KR
$257.40 13.71%
BE